Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer
Histopathology · 2024
DOI: 10.1111/his.15134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Sonay K Ozturk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KWF kankerbestrijding.
Abstract (Originalsprache)
Aims
Lymph node metastases (LNM) are one of the most important prognostic indicators in solid tumours and a major component of cancer staging. Neoadjuvant therapy might influence nodal status by induction of regression. Our aim is to determine the prevalence and role of regression of LNM on outcomes in patients with rectal cancer. Methods and results Four independent study populations of rectal cancer patients treated with similar regimens of chemoradiotherapy were pooled together to obtain a total cohort of 469 patients. Post‐treatment nodal status (ypN) and signs of tumour regression (Reg) were incorporated to form three‐tiered (ypN− Reg+, ypN− Reg− and ypN+) and four‐tiered (ypN− Reg+, ypN− Reg−, ypN+ Reg+ and ypN+ Reg−) classifications. In our cohort, 31% of patients presented with ypN+ rectal cancer. As expected, we found significantly worse overall survival (OS) in ypN+ patients compared to ypN− patients ( P = 0.002). The percentage of ypN− patients with lymph nodes with complete regression was 20% in our cohort. While node‐negative patients with and without regression had similar OS ( P = 0.09), disease‐free survival (DFS) was significantly better in node‐negative patients with regression ( P = 0.009).
Conclusions
Regression in lymph nodes is frequent, and node‐negative patients with evidence of lymph node regression have better DFS compared to node‐negative patients without such evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Department of Surgical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands.
- Department of Pathology, St Vincent's University Hospital, Dublin, Ireland.
- Department of Surgical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Department of Oncology, University Medical Centre Groningen, Groningen, the Netherlands.
- Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
ORCID-Profile: Iris D Nagtegaal
Förderung
- KWF kankerbestrijding
Zitieren
APA
Ozturk, S. K., Martinez, C. G., Mens, D., Verhoef, C., Tosetto, M., Sheahan, K., de Wilt, J. H. W., Hospers, G. A. P., van de Velde, C. J. H., Marijnen, C. A. M., van der Post, R. S., & Nagtegaal, I. D. (2024). Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer. Histopathology. https://doi.org/10.1111/his.15134
Vancouver
Ozturk SK, Martinez CG, Mens D, Verhoef C, Tosetto M, Sheahan K, et al. Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer. Histopathology. 2024. doi:10.1111/his.15134
BibTeX
@article{Ozturk2024,
author = {Ozturk, Sonay K and Martinez, Cristina G and Mens, David and Verhoef, Cornelis and Tosetto, Miriam and Sheahan, Kieran and de Wilt, Johannes H W and Hospers, Geke A P and van de Velde, Cornelis J H and Marijnen, Corrie A M and van der Post, Rachel S and Nagtegaal, Iris D},
title = {Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer},
journal = {Histopathology},
year = {2024},
doi = {10.1111/his.15134}
}
EUVIMED